Pozanicline

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Pozanicline
Pozanicline.svg
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC11H16N2O
Molar mass192.258 g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Pozanicline (INN,[1] codenamed ABT-089) is a drug developed by Abbott, that has nootropic and neuroprotective effects.[2][3][4] Animal studies suggested it useful for the treatment of ADHD[5] and subsequent human trials have shown ABT-089 to be effective for this application.[6] It binds with high affinity subtype-selective to the α4β2 nicotinic acetylcholine receptors and has partial agonism to the α6β2 subtype,[7][8] but not the α7 and α3β4 subtypes familiar to nicotine. It has particularly low tendency to cause side effects compared to other drugs in the class,[9][10] making it an exciting candidate for clinical development.

Synthesis[edit]

Pozanicline is synthesized from 2-methyl-3-hydroxypyridine and Boc-L-Prolinol through a dehydration reaction followed by deprotection of the nitrogen atom of prolinol[11]

References[edit]

  1. ^ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 62" (PDF). World Health Organization. p. 257. Archived (PDF) from the original on 18 May 2016. Retrieved 3 January 2017.
  2. ^ Lin, NH; Gunn, DE; Ryther, KB; Garvey, DS; Donnelly-Roberts, DL; Decker, MW; Brioni, JD; Buckley, MJ; Rodrigues, AD; Marsh, KG; Anderson, DJ; Buccafusco, JJ; Prendergast, MA; Sullivan, JP; Williams, M; Arneric, SP; Holladay, MW (Jan 1997). "Structure-activity studies on 2-methyl-3-(2(S)-pyrrolidinylmethoxy) pyridine (ABT-089) an orally bioavailable 3-pyridyl ether nicotinic acetylcholine receptor ligand with cognition-enhancing properties". Journal of Medicinal Chemistry. 40 (3): 385–90. doi:10.1021/jm960233u. PMID 9022806.
  3. ^ Sullivan, JP; Donnelly-Roberts, D; Briggs, CA; Anderson, DJ; Gopalakrishnan, M; Xue, IC; Piattoni-Kaplan, M; Molinari, E; Campbell, JE; McKenna, DG; Gunn, DE; Lin, NH; Ryther, KB; He, Y; Holladay, MW; Wonnacott, S; Williams, M; Arneric, SP (Oct 1997). "ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective properties". Journal of Pharmacology and Experimental Therapeutics. 283 (1): 235–46. PMID 9336329.
  4. ^ Decker, MW; Bannon, AW; Curzon, P; Gunther, KL; Brioni, JD; Holladay, MW; Lin, NH; Li, Y; Daanen, JF; Buccafusco, JJ; Prendergast, MA; Jackson, WJ; Arneric, SP (Oct 1997). "ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine dihydrochloride]: II. A novel cholinergic channel modulator with effects on cognitive performance in rats and monkeys". Journal of Pharmacology and Experimental Therapeutics. 283 (1): 247–58. PMID 9336330.
  5. ^ Prendergast, MA; Jackson, WJ; Terry, AV (Mar 1998). "Jr, Decker MW, Arneric SP, Buccafusco JJ. Central nicotinic receptor agonists ABT-418, ABT-089, and (−)-nicotine reduce distractibility in adult monkeys". Psychopharmacology. 136 (1): 50–8. doi:10.1007/s002130050538. PMID 9537682.
  6. ^ Wilens, TE; Verlinden, MH; Adler, LA; Wozniak, PJ; West, SA (Jun 2006). "ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-deficit/hyperactivity disorder in adults: results of a pilot study". Biological Psychiatry. 59 (11): 1065–70. doi:10.1016/j.biopsych.2005.10.029. PMID 16499880.
  7. ^ Marks MJ, Wageman CR, Grady SR, Gopalakrishnan M, Briggs CA (May 2009). "Selectivity of ABT-089 for alpha4beta2* and alpha6beta2* nicotinic acetylcholine receptors in brain". Biochemical Pharmacology. 78 (7): 795–802. doi:10.1016/j.bcp.2009.05.022. PMC 2772152. PMID 19481067.
  8. ^ Anderson DJ, Malysz J, Grønlien JH, El Kouhen R, Håkerud M, Wetterstrand C, Briggs CA, Gopalakrishnan M (June 2009). "Stimulation of dopamine release by nicotinic acetylcholine receptor ligands in rat brain slices correlates with the profile of high, but not low, sensitivity alpha4beta2 subunit combination". Biochemical Pharmacology. 78 (7): 844–51. doi:10.1016/j.bcp.2009.06.024. PMID 19555668.
  9. ^ Rueter, LE; Anderson, DJ; Briggs, CA; et al. (2004). "ABT-089: pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders". CNS Drug Rev. 10 (2): 167–82. doi:10.1111/j.1527-3458.2004.tb00011.x. PMC 6741767. PMID 15179445.
  10. ^ Wilens, TE; Decker, MW (Oct 2007). "Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: focus on cognition". Biochemical Pharmacology. 74 (8): 1212–23. doi:10.1016/j.bcp.2007.07.002. PMC 2974320. PMID 17689498.
  11. ^ Rueter, Lynne E.; Anderson, David J.; Briggs, Clark A.; Donnelly-Roberts, Diana L.; Gintant, Gary A.; Gopalakrishnan, Murali; Lin, Nan-Horng; Osinski, Mark A.; Reinhart, Glenn A.; Buckley, Michael J.; Martin, Ruth L.; McDermott, Jeffrey S.; Preusser, Lee C.; Seifert, Terese R.; Su, Zhi; Cox, Bryan F.; Decker, Michael W.; Sullivan, James P. (2006). "ABT-089: Pharmacological Properties of a Neuronal Nicotinic Acetylcholine Receptor Agonist for the Potential Treatment of Cognitive Disorders". CNS Drug Reviews. 10 (2): 167–182. doi:10.1111/j.1527-3458.2004.tb00011.x. PMC 6741767. PMID 15179445.